MGD management needed for ocular prosthesis wearers

Article

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD).

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD), states the latest paper in the British Journal of Ophthalmology.

A team headed by Dr Jin Sook Yoon, Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Korea, assigned a survey to 30 consecutive patients with unilateral ocular prosthesis to identify MGD-related ocular symptoms.

All patients underwent slit lamp examination, meibography imaging and Fourier-domain (FD) optical coherence tomography (OCT) scanning on both eyelids. The main outcome measures were assessed using intra-individual comparison between the eyelids of a prosthetic eye and paired normal eyelids.

Eyelids with ocular prosthesis presented with significantly higher scores for ocular symptoms, lid margin abnormality, meibomian gland expression and meibography compared to normal eyelids.

Tear parameters in the eyelids with prosthetic eyes were significantly lower than normal eyelids. Overall ocular symptom score was significantly positively correlated with meibography score and negatively associated with tear parameters. Clinical evaluation and management recommendations for MGD would highly benefit patients with prosthetic eyes, especially those demonstrating ocular discomfort.

Please click here to read the abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.